Romanovsky Dmitry Iosifovich

Romanovsky Dmitry Iosifovich - founder and director of the Institute of Pharmacology and Biochemistry of the National Academy of Sciences of Belarus (since 2006), founder of the Academpharm pharmaceutical plant in the National Academy of Sciences of Belarus (since 2009), director of science, managing partner of Mosmedpreparaty group of companies and Nanogen, founder of the Orotest company for the development and production of biochips, immunochemical and molecular biological diagnostics.

He graduated from the Minsk State Medical Institute (Belarus) and the Medical School of Nagasaki University (Japan). Student of the outstanding Soviet and Russian pharmacologist - laureate of the USSR State Prize, Professor B.V. Dubovik .

From 1997 to 2002 he trained and worked in Japan, at the same time until 2004 he headed the laboratory of experimental medicine, pharmacology and toxicology of the Belarusian State Medical University that he created . During this period, he completed a series of studies on the molecular pharmacology of the cell cycle and apoptosis, described the structural and functional interactions of c-myc and bcl-2 proteins, their role in hormone-dependent carcinogenesis. He is the author of a number of patents on chemotherapy of tumor and precancerous processes. He participated in the leadership and implementation of international research programs to study the consequences of the Chernobyl accident , including under the auspices of the World Health Organization .

In 2002, he initiated the first professional forum - the National Symposium “Belarusian Pharmacology” under the leadership of the Ministry of Health of the Republic of Belarus , the National Academy of Sciences of Belarus and the Belarusian State Concern for the Production and Sale of Pharmaceutical and Microbiological Products “Belbiopharm” ^[1] .

From 2004 to 2006, he was the head of the Center for Pharmacology and Toxicology created by him, deputy director for research at the Institute of Physical and Organic Chemistry of the National Academy of Sciences of Belarus .

Since 2006 - Director of the Institute of Pharmacology and Biochemistry of the National Academy of Sciences of Belarus , established on the basis of the Center for Pharmacology and Toxicology of the Institute of Physical and Organic Chemistry and the Institute of Biochemistry of the National Academy of Sciences of Belarus.

In 2007-2008 initiated the development of industrial pharmacy at the Academy of Sciences, the innovative development of pharmaceuticals for the countries of the former USSR ^{[2] [3]} , the scientific support of import substitution in the healthcare sector ^[4] . On January 18, 2008, the Institute was visited by the President of the Republic of Belarus and senior officials. Alexander Lukashenko gave instructions on the development of a testing and production base, ensuring the implementation of state tasks to create new generations of modern pharmacology, commissioning the first and second phases of industrial infrastructure ^[2] . The head of state called “seen in the workshop and at a small improvised exhibition of manufactured products“ a good example of how scientific institutions should work in modern conditions ” ^[5] .

In 2008, D. I. Romanovsky introduced to the Administration of the President of the Republic of Belarus and the Government a package proposal and a roadmap for the development of the pharmaceutical industry in the Republic. Based on these proposals, a state program for the development of the pharmaceutical industry was developed, and subsequently a holding was created that united Belarusian pharmaceutical manufacturers.

D.I. Romanovsky continued the development of Soviet-Indian cooperation in the pharmaceutical field, the vector of Belarusian-Indian cooperation was laid after meetings in the government with the promoter and president of Cipla, Dr. Yusuf Hamid . ^{[6] [7] [8] [9]} .

In 2009, together with prof. B.V. Dubovik restored the work of the Belarusian Scientific Society of Pharmacologists and Toxicologists, founded the tradition of the annual scientific conferences “Belarusian Medicines” and “Experimental and Clinical Pharmacology” with international participation. He founded the scientific journals “Experimental and Clinical Pharmacology” and “World of Drugs”.

In 2010, under the leadership of D. I. Romanovsky, for the first time at the Academy of Sciences “from scratch” the Akadempharm pharmaceutical plant was built and put into design capacity ^[10] - an innovative full-cycle pharmaceutical enterprise, the first high-tech production in the republic, affiliated with a research center. The plant was launched in September 2010 with the participation of senior government officials.

At the invitation of D. I. Romanovsky, in 2010 the head of Cipla, Dr. Yusuf Hamid, visited the Republic of Belarus, the Institute of Pharmacology and Biochemistry, the Akadempharm plant ^{[11] [12]} . Meetings were held at the state level with the Prime Minister of the Republic of Belarus A. V. Kobyakov, Chairman of the Presidium of the National Academy of Sciences of Belarus M. V. Myasnikovich, and the leadership of the Ministry of Health ^[13] . The first ever visit to the countries of the former USSR of the head of the largest pharmaceutical company with a global presence and the initiatives proposed by Yusuf Hamid and Dmitry Romanovsky became a trigger for the further development of the pharmaceutical industry and science in Belarus and the former Soviet Union. Dr. Yusuf Hamid was elected an honorary professor at the Institute of Pharmacology and Biochemistry of the NAS of Belarus, and in November 2017, a foreign member of the NAS of Belarus ^[14] .

On November 1, 2010, the European Commissioner for Health John Dalli visited the Institute of Pharmacology and Biochemistry and the Academpharm enterprise. ^[15] According to media reports, as a result of the first-ever interaction with the European regulator in the field of pharmaceuticals and healthcare at the Institute of Pharmacology and Biochemistry, the European Commissioner "praised the achievements of scientists in creating original medicines and certifying industries in accordance with GMP standards." ^[sixteen]

Since 2011 - Director of Science at the Institute for Development and Security, chief pharmacologist, head of the Development and Implementation Center, member of the Board of Directors of Ferein JSC, Bryntsalov-A PJSC and a number of innovative startup companies. Director of Science, managing partner of the group of companies Moscow Medical Preparations (Mosmedpreparaty) and Nanogen. He founded the Orotest company for the development and production of immunochemical and molecular biological tests for the rapid diagnosis of HIV / AIDS, hepatitis B and C, the identification of tumor markers and a predisposition to genetically determined diseases.

The head, executive officer of a number of works on the instructions of the State Committee on Science and Technology, the Belarusian Innovation Fund, was a member of a specialized state expert council, scientific and technical councils. Together with prof. B.V. Dubovik and a team of employees conducted biomedical tests and developed dozens of pharmaceuticals: Ehingin, Trimumal, Fitonsol, Selenobel, Polymed, Bufatin, Groceprol, Valikar , "Neyramin", "Inocardine", "Tetracard", "Immugenin", "Aspargit", "Leyargunal", "Hydrogel matrices", "Hydroxyapatite", "Levothyroxine", "Imatinib" and others. Head of the development of domestic vitamins of the series "" Univ " ^[17] and metabotropic complexes for various purposes, some original and 100 of generic ekarstvennyh funds. Developed a complete line of probiotic agents.

For the metabolic protection of the myocardium based on L-arginine succinate, the drug “Cardinosine”, based on arginine, lysine, taurine, “Lizargin”, developed for long-term therapy of coronary heart disease and the prevention of repeated myocardial infarction and strokes, was developed and put into production. The result of joint work with IFCS was the creation of the composite drug “Leyargunal”, which has immunostimulating and adaptogenic properties (used for general variable immunodeficiency against the background of continuously recurring infectious and inflammatory diseases). Based on the original dipeptide, the immunomodulating drug Immugenin has been developed, which has high immunotropic activity (it has a stimulating effect on the processes of profiling, differentiation and migration of T and B lymphocytes, a positive effect on the indicators of cellular humoral immunity). ^[18]

He developed and introduced into production a medical autoinjector for use in military and emergency medicine. Domestic auto-injector is a pioneer development available to individual companies in the world.

He developed and introduced into production more than 10 test systems for immunochemical diagnosis of diseases and pathological conditions, including immunodiagnostics for the detection of HIV / AIDS, hepatitis B and C, non-invasive monitoring of tumor markers CA-125, CA-15-3, CA-19- 9 and others

One of the initiators of the formation of the State Scientific Research Institute “Pharmacology and Pharmacy”, the State Enterprise “Medicinal Substances”, the subprogram “Amino Acids” of the State Scientific and Technical Program “Medicines”. Co-author of 7 monographs, an encyclopedic dictionary, the study guide "Antibiotics", has published more than a hundred scientific articles.

He was a co-author of the development, deputy head of the State integrated target scientific and technical program of the SCSSTP 12 “Medicine and Pharmacy”, 2011-2015, approved by the Council of Ministers of the Republic of Belarus on February 01, 2011 No. 116, subprograms of the GPNI 14 “Fundamental and Applied Medicine and Pharmacy”, 2011–2015 and GPPNI 39 “Pharmaceutical Technologies”, 2009–2011. The programs were carried out at the Academy of Sciences and the Ministry of Health as the basis of scientific and scientific and technical support for the creation of effective medical technologies and medicines with the aim of introducing new methods of diagnosis, treatment and prevention of socially significant diseases and mastering the production of competitive import-substituting medical devices that increase the duration and quality of life the population of the Republic of Belarus, as well as increasing social and labor potential and demographic security country. ^[nineteen]

Laureate of the Prize of the National Academy of Sciences of Belarus for the creation of the medicine “Flustop” (2010) ^{[20] [21] [22] [23]} . The Republic of Belarus has become the second country in the world, in an incredibly short time, mastered the production of antiviral agents for the prevention and treatment of pandemic influenza.

Nearby domestic and foreign media, the creation of “Flustop” is called the event of 2010. The authoritative government publication “ Sovetskaya Belorussia ” wrote on this subject: “Scientists from the Institute of Pharmacology and Biochemistry of the National Academy of Sciences quickly, right in the midst of an epidemic and panic, developed, in collaboration with the largest Indian pharmaceutical company,“ our answer ”to the flu is the drug fluop. As a result, he became the winner of the NAS competition for the best innovative project of the year. “Belarusian Tamiflu”, both pharmacologists and doctors confirm, is not inferior in effectiveness to a foreign one: the infection slows down in a matter of hours, and in 5 days it completely expels the disease from the body. Moreover, there is a clear superiority in something behind our drug: flustop costs the patient three times cheaper! ” ^[24] “ Flustop ” ^[25] became the first domestic drug for targeted therapy of seasonal viral diseases. ^[26]

In 2011, under the leadership of D. I. Romanovsky, the Akadempharm plant mastered the release of Imatinib , the first domestic drug for oncological chemotherapy in the territory of the former USSR.

He initiated a project to transfer to the Russian Federation full-cycle technologies for the production of biotechnological preparations of various pharmacotherapeutic groups. He organized a number of international cooperation projects in pharmaceuticals and medicine in Singapore, India, China, Egypt, Jordan, the United Arab Emirates.

He specializes in psychoneuropharmacology, biopharmacology, radiation, protective and molecular pharmacology, preclinical and clinical trials of drugs and pharmaceutical substances, industrial pharmacy and biotechnology. As an expert, he is known for his unmistakable predictions ^{[27] of the} pharmaceutical future ^[28] , sharp polemical speeches and concern for reality.